Accessibility Menu
China Sxt Pharmaceuticals Stock Quote

China Sxt Pharmaceuticals (NASDAQ: SXTC)

$5.07
(-21.6%)
-1.40
Price as of February 3, 2026, 12:23 p.m. ET

KEY DATA POINTS

Current Price
$5.07
Daily Change
(-21.6%) $1.40
Day's Range
$5.00 - $6.40
Previous Close
$6.47
Open
$5.60
Beta
1.94
Volume
217,390
Average Volume
159,125
Market Cap
$828M
Market Cap / Employee
$6.47M
52wk Range
$4.01 - $1,176.00
Revenue
N/A
Gross Margin
0.22%
Dividend Yield
N/A
EPS
-$0.24
CAPs Rating
N/A
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

China Sxt Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
SXTC-98.69%-100%-91.79%-100%
S&P+15.49%+82.14%+12.74%+176%

China Sxt Pharmaceuticals Company Info

China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

News & Analysis

No results found

No news articles found for China Sxt Pharmaceuticals.

Financial Health

General

No data available

No data available for this period.

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

No data available

No data available for this period.

Liabilities

No data available

No data available for this period.

Ratios

No data available

No data available for this period.

Cash Flow

No data available

No data available for this period.

Valuation

MetricYoY Change

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.